The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
 
Laurie Helen Sehn
Honoraria - Abbvie; Amgen; AstraZeneca; BeiGene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Beigene; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Janssen; Kite, a Gilead company; Merck; Roche/Genentech; Sandoz-Novartis; Seagen; Teva; TG therapeutics
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Martine Chamuleau
Consulting or Advisory Role - Abbvie; Incyte; Novartis
Research Funding - Bristol-Myers Squibb; Genmab; Gilead Sciences
 
Georg Lenz
Honoraria - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Constellation Pharmaceuticals; Genmab/Seattle Genetics; Gilead Sciences; Incyte; Janssen-Cilag; Novartis; Roche/Genentech; SOBI
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; Bristol-Myers Squibb; Genase Therapeutics; Genmab/Seattle Genetics; Gilead Sciences; Hexal; Immagene; Incyte; Janssen-Cilag; Karyopharm Therapeutics; Lilly; Miltenyi Biomedicine; MorphoSys; Novartis; PentixaPharm; Roche/Genentech; Sobi
Research Funding - AGIOS; Aquinox; AstraZeneca; Bayer; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche/Genentech; Verastem
Expert Testimony - Roche
Travel, Accommodations, Expenses - Abbvie; Gilead Sciences; Janssen-Cilag; Roche/Genentech
 
Michael Clausen
Consulting or Advisory Role - Abbvie; Genmab; Janssen; Kite, a Gilead company
Speakers' Bureau - Abbvie; Janssen
Travel, Accommodations, Expenses - Abbvie; AstraZeneca/Merck; Genmab; Janssen
 
Corinne Haioun
Honoraria - Amgen; Celgene; Gilead Sciences; Janssen-Cilag; Miltenyi Biotec; Roche; Takeda
 
Koji Izutsu
Honoraria - Abbvie; Abbvie; Allergan; AstraZeneca; Bayer; Bristol Myers Squibb; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; MSD; MSD; Mundipharma; Novartis; Ono Pharmaceutical; SymBio Pharmaceuticals; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bayer; Celgene; Kyowa Kirin; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Andrew John John Davies
Honoraria - Abbvie; AstraZeneca; Celgene/Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Kite, a Gilead company; Roche
Consulting or Advisory Role - Abbvie; Acerta Pharma; Celgene; Gilead Sciences; Janssen; Kite, a Gilead company; Regeneron; Roche
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); MSD; Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche
 
Jun Zhu
No Relationships to Disclose
 
Toshiko Oki
Employment - Abbvie
 
Edith Szafer-Glusman
Employment - Abbvie
 
Rebekah Conlon
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Hueiyu Chiou
Employment - Abbvie
 
David Ipe
Employment - Abbvie
 
Brian Elliott
Employment - Genmab; Novartis
Stock and Other Ownership Interests - Genmab; Novartis
Patents, Royalties, Other Intellectual Property - Patents pending related to Genmab development of epcoritamab
Travel, Accommodations, Expenses - Genmab; Novartis
 
Jun Wu
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Gilles A. Salles
Stock and Other Ownership Interests - Owkin
Honoraria - Abbvie; Bayer; Incyte; Regeneron
Consulting or Advisory Role - Abbvie; BeiGene; BMS; Debiopharm Group; Epizyme; Genmab; Incyte; incyte; Ipsen; Janssen; Kite/Gilead; Loxo/Lilly; Miltenyi Biotec; Molecular Partners; morphosys; Nordic Nanovector; Novartis; RAPT Therapeutics; Roche/Genentech; Takeda; Velosbio